semaj83/ctmatch_classification huggingface dataset:
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypertension Hypertensive patients who have never taken Micombi Tablets
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Hypercholesterolemia Type 2 Diabetes Hypertension Patients meeting the following will be included in the study Patients giving voluntary written consent to participate in the study Male or female patients 50 years of age or older (at informed consent) Hypercholesterolemia patients (Untreated patients: LDL-C level ≥140 mg/dL; treated patients: LDL-C level ≥120 mg/dL) Type 2 diabetes patients (HbA1c level ≥6.1% (JDS criteria), with or without history of drug therapy) Hypertension patients (SBP ≥130 mmHg or DBP ≥80 mmHg, with or without history of drug therapy) Patients with two or more of the following risk factors Male years of age or older Smoker  Patients meeting the following will be excluded from the study Patients receiving rosuvastatin, pitavastatin, or atorvastatin therapy within one month prior to informed consent Patients judged to have familial hypercholesterolemia Patients with a serum triglyceride level of ≥400 mg/dL Patients with a history of myocardial infarction Patients with a history of coronary revascularization (PCI or CABG) Patients with a history of treatment of unstable angina Patients with a history of cerebrovascular accident (excluding asymptomatic lacunar infarction) Heart failure patients Patients with a history of hypersensitivity to statins
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriatic Arthritis Males or females, aged ≥ 18 years at time of consent Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration Meet the Classification for Psoriatic Arthritis (CASPAR) for PsA at time of screening Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs) May not have axial involvement alone Concurrent Tx allowed with methotrexate, leflunomide, or sulfasalazine Have ≥ 3 swollen AND ≥ 3 tender joints Males & Females must use contraception Stable dose of NSAIDs, narcotics and low dose oral corticosteroids allowed Have at least one ≥2 cm psoriasis lesion  Pregnant or breast feeding History of allergy to any component of the investigational product Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF) blocker
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.5-11.0,  Rhinitis Perennial Aged 6 months through 11 years Patients with perennial allergic rhinitis  Neither serum specific IgE antibody or skin reaction is positive for the antigen of perennial allergy Nasal symptom score is 0 for either sneezing or nasal discharge, or sum of these two score is less than 3, or nasal congestion score is 4 Patients with vasomotor rhinitis or eosinophilic rhinitis
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriatic Arthritis Subjects must satisfy the following to be enrolled in the study Male or female, aged ≥ 18 years at time of consent Must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted Able to adhere to the study visit schedule and other protocol requirements Have a documented diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 3 months duration Meet the Classification for Psoriatic Arthritis (CASPAR) for PsA at time of screening Have ≥ 3 swollen AND ≥ 3 tender joints Have not been previously treated with disease-modifying antirheumatic drugs (DMARDS) (small molecules or biologics) Be receiving treatment on an outpatient basis If taking oral corticosteroids, must be on a stable dose of prednisone ≤ 10 mg/day or equivalent for at least 1 month prior to screening  History of clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease Any condition, including the presence of laboratory abnormalities that places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study Clinically significant abnormality on 12-lead electrocardiography (ECG) at Screening Pregnant or breast feeding History of allergy to any component of the IP Hepatitis B surface antigen positive at screening Hepatitis C antibody positive at screening AST/SGOT and/or ALT/SGPT > 1.5 x ULN and total bilirubin > ULN or albumin < lower limit of normal (LLN) History of positive Human Immunodeficiency Virus (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease) Active tuberculosis or a history of incompletely treated tuberculosis
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Gastric Cancer Age 20~80 Informed consent No other malignancies Proximal gastric cancer met by following conditions Lesion located on proximal stomach (upper one third) Lesion below 5cm in size Lesion confined to proper muscle depth (cT2) No evidence of metastatic enlarged LN on #5, 6, 4d, 10 basins and other distant metastasis. (cN1)  If patients is only suitable to total gastrectomy, he will be excluded
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Kawasaki Disease History of KD before the age of 18, with or without macroscopic coronary lesions in the childhood phase. (KD group only) years old or older at the time of the study Agree on participating to all explorations of the study Accept genotyping Absence of cardiovascular risk factors  Atypical KD (KD group only) Documented or suspected coronary ischemia Refusal to participate to the study or sign the consent Contra-indication to the injection of iodinated contrast agents (allergy, renal failure) Hypersensitivity to dobutamine No effective contraception method for females with child bearing potential Breastfeeding, or pregnant females Treatment modifying endothelial reactivity History of severe intolerance to iodinated contrast agents Subjects who can't hold their breath for at least 20 seconds
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 3.0-999.0,  Strep Throat Male and Female subjects three (3) years of age or older Patients exhibiting at least 3 of the following symptoms fever sore throat swollen lymph nodes in the neck redness of the throat and tonsils white or yellow patches on the tonsils Must be able to collect 2 throat swab samples from patient  Patients currently undergoing antibiotic treatment will be excluded from study
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 3.0-999.0,  Group A Streptococcus Strep Throat Presence of sore throat Redness of the posterior pharyngeal wall Tonsillar exudate Tonsillar swelling Tender anterior cervical adenopathy Fever, > 38º C (100.4ºF) at presentation or within past 24 hours Other symptoms that may be present, in addition to above symptoms for GAS Rash, typical of scarlet fever Abnormal tympanic membranes Palatal petechiae  Subjects treated with antibiotics currently or within the previous week (7 days) are not to be included in this study At clinical sites requiring informed consent, unable to understand and consent to participation; for minors this includes parent or legal guardian
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 1.0-10.0,  Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin Patients diagnosed with Kawasaki disease (incipient cases only) with 5 or more of the 6 major symptoms of Kawasaki disease Patients refractory to initial IVIG therapy (a single administration at 2 g per kg body weight) Patients with a fever of 37.5ºC or higher axillary temperature at the time of enrollment Patients to whom the study drug can be administered by day 8 of disease  Patients who have received vaccination with Bacille Calmette-Guérin (BCG) vaccine within 6 months before the enrollment Patients with a complication, or a history within 6 months before the enrollment of, serious infections requiring hospitalization Patients with a complication, or a history within 6 months before the enrollment of, opportunistic infections Patients complicated with active tuberculosis, active hepatitis B or C, or patients confirmed to be hepatitis B virus carriers or a history of hepatitis B Patients confirmed to have HIV infection, or patients with a family history of HIV infection Patients who have a history of receiving treatment with infliximab or other biological products Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving consent
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.083-18.0,  Kawasaki Disease Coronary Aneurysm Treatment arm: Patients aged 1 month to 18 years with confirmed KD will be included in the study if they meet the following Patients with dilation of the right or left anterior descending coronary artery beyond a z-score of +3 during the acute febrile phase of KD Patients with aneurysms of the right or left main coronary arteries during the acute febrile phase of KD Patients with refractory KD after initial treatment with IVIG and dilated coronary arteries on an echocardiogram during the first month of KD Comparison arm: Patients aged 1 month to 18 years with confirmed KD, who do not meet to be included in the treatment group Patients with right or left anterior descending coronary artery measurements below a z-score of +3 during the acute febrile phase of KD  The following patients will be excluded from this study Patients with clinically incomplete KD Patients whose parents refuse to administer doxycycline Patients with acute renal failure Patients with chronic liver and kidney disease
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.0-16.0,  Drug Hypersensitivity Participation will be proposed to any children (0 to 16 years) receiving one or several drug(s) and developing one of the following clinical manifestations: urticaria, maculopapular rash, bullous eruption, flush, anaphylaxis, serum sickness-like disease, SJS, TEN, DRESS or fever linked to drug intake  Patients will be excluded if the symptoms occur more than 72 hours after any treatment was stopped or if the symptoms are clearly linked to another cause (measles, rubeola, roseola, varicella, fifth disease, Gianotti-Crosti syndrome, scarlet fever, Gibert's pityriasis or food allergy)
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Immune Thrombocytopenia Given written informed consent Male or female aged ≥ 19 Primary immune thrombocytopenia (ITP) Platelet <20x10^9 /L Patients who have taken adrenal cortical hormones and/or other immunosuppressive medications should maintain their stable doses before and during this study  Patients who have participate in other interventional study within 30 days Inability in written/verbal communication Engaged with an elective surgery Pregnant or breast-feeding women Women of childbearing potential who do not agree with contraception during this study Patients who had experienced any hypersensitivity or shock with study drug or active ingredient Refractory to immunoglobulin therapy Secondary immune thrombocytopenia HIV-associated ITP Lupus-associated ITP
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Healthy Volunteers Male or female of any race 50 years old, inclusive Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia) Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG, a medical history, and blood test (complete blood count and sickle cell trait/disease screening) Meets specific demographic requirements for the monitoring device under study Willing and able to provide written informed consent Able to participate for the duration of the evaluation  A room-air baseline % modulation < 1.5% on all four fingers on the test hand Under 18 years or over 50 years of age Pregnant and/or lactating women Hypertension: on three consecutive readings, systolic pressure greater than 145 mm Hg or diastolic pressure greater than 90 mm Hg Ventricular premature complexes (VPC's) that are symptomatic or occur at a rate of more than four per minute History of seizures (except childhood febrile seizures) or epilepsy History of unexplained syncope Daily or more frequent use of anxiolytic drugs (benzodiazepines) for treatment of anxiety disorder Recent history of frequent migraine headaches: average of two or more per month over the last year Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)